Vitamin K2 improves the hematopoietic supportive functions of bone marrow stromal cells in vitro: A possible mechanism of improvement of cytopenia for refractory anemia in response to vitamin K2 therapy

Stem Cells and Development

Volumn 13, Issue 5, 2004, Pages 449-451

  Miyazawa, Keisuke ^a   Aizawa, Shin ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Nihon University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FARNOQUINONE; TUMOR NECROSIS FACTOR ALPHA; ANTIFIBRINOLYTIC AGENT; CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOPENIA; DRUG SAFETY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; IN VITRO STUDY; LETTER; LONG TERM CARE; MYELODYSPLASTIC SYNDROME; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REFRACTORY ANEMIA; STROMA CELL; ADENOVIRUS; ANEMIA; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; COCULTURE; CYTOLOGY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; TIME;

ADENOVIRIDAE; ANEMIA; ANTIFIBRINOLYTIC AGENTS; ANTIGENS, CD34; BONE MARROW CELLS; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; STROMAL CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN K 2;

EID: 8144224444     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2004.13.449     Document Type: Letter

References (10)

1. Aizawa S, M Nakano, O Iwase, M Yaguchi, M Hiramoto, H Hoshi, R Nabeshima, D Shima, H Handa and K Toyama. (1999). Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23:239-246.
2. Aizawa S, M Hiramoto, H Hoshi, K Toyama, D Shima and H Handa. (2000). Establishment of stromal cell line from an MDS RA patient which induced an apoptotic change in hematopoietic and leukemic cells in vitro. Exp Hematol 28:148-155.
3. Coutinho LH, CG Geary, J Chang, C Harrison and NG Testa. (1990). Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 75:16-25.
4. Flores-Figueroa E, G Gutierrez-Espindola, JJ Montesinos, RM Arana-Trejo and H Mayani. (2002). In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:677-686.
5. Yaguchi M, K Miyazawa, T Katagiri, J Nishimaki, M Kizaki, K Tohyama and K Toyama. (1997). Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia 11:779-787.
6. Miyazawa K, M Yaguchi, K Funato, A Gotoh, Y Kawanishi, Y Nishizawa, A Yuo and K Ohyashiki. (2001). Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15:1111-1117.
7. Yaguchi M, K Miyazawa, M Otawa, Y Ito, Y Kawanishi and K Toyama. (1999). Vitamin K2 therapy for a patient with myelodysplastic syndrome. Leukemia 13:144-145.
8. Takami A, S Nakao and Y Ontachi. (1999). Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 64:24-26.
9. Miyazawa K, J Nishimaki, K Ohyashiki, S Enomoto, S Kuriya, R Fukuda, T Hotta, M Teramura, H Mizoguchi, T Uchiyama and M Omine. (2000). Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 14:1156-1157.
10. Takami A, H Asakura and S Nakao. (2002). Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol 81:16-19.